| Withdrawn | Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gyn NCT07226102 | City of Hope Medical Center | N/A |
| Recruiting | Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent O NCT07144826 | Ohio State University Comprehensive Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Brea NCT06630325 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in S NCT06855706 | Roswell Park Cancer Institute | N/A |
| Active Not Recruiting | e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gyn NCT05786456 | City of Hope Medical Center | N/A |
| Withdrawn | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients W NCT03735589 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Withdrawn | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer NCT05368506 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Recruiting | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000 | Northwestern University | Phase 2 |
| Withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial NCT05238831 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Active Not Recruiting | Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage NCT05276973 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Tr NCT05415709 | Ohio State University Comprehensive Cancer Center | EARLY_Phase 1 |
| Recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors NCT07259304 | University of Southern California | — |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa NCT04673448 | University of Washington | Phase 1 |
| Recruiting | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea NCT04616534 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" NCT04314401 | National Cancer Institute (NCI) | — |
| Recruiting | Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer NCT04794322 | Massachusetts General Hospital | — |
| Completed | Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes NCT04501913 | City of Hope Medical Center | — |
| Active Not Recruiting | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian NCT04095364 | NRG Oncology | Phase 3 |
| Completed | A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors NCT03784677 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Active Not Recruiting | Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cance NCT03943173 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer NCT03939481 | SWOG Cancer Research Network | — |
| Active Not Recruiting | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistan NCT03907527 | Precigen, Inc | Phase 1 |
| Terminated | Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer NCT03606486 | University of Washington | N/A |
| Active Not Recruiting | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Insta NCT03428802 | Rutgers, The State University of New Jersey | Phase 2 |
| Active Not Recruiting | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |